DARBITOP 25MG

Darbitop 25 Injection 0.42 ml is classified as a ‘blood-forming agent’ and is primarily utilized to treat anaemia (a low red blood cell count) in individuals with long-term serious (chronic) kidney disease and those undergoing chemotherapy for certain types of cancer (excluding cancers of the bone marrow or blood cells). This injection aids in reversing anaemia and decreasing the necessity for blood transfusions. Anaemia arises when the body has a reduced quantity of red blood cells or haemoglobin. In cases of chronic kidney disease, the kidneys become damaged and fail to filter the blood effectively, resulting in anaemia.

Darbitop 25 Injection 0.42 ml contains the protein ‘Darbepoetin alfa’, which functions by signaling the bone marrow to produce more red blood cells. It acts as a biologic response modifier and an erythropoiesis-stimulating protein. In chronic kidney disease, when the kidneys do not generate enough ‘erythropoietin protein’ that is essential for red blood cell formation, Darbitop 25 Injection 0.42 ml promotes the production of this protein in the bone marrow.

The injection will be administered by a healthcare professional. Self-administration is not advised. Common side effects associated with Darbitop 25 Injection 0.42 ml include shortness of breath, cough, low blood pressure during dialysis, headache, body aches, diarrhea, pain at the injection site, and abdominal discomfort. Most of these side effects do not necessitate medical intervention and typically resolve on their own over time. However, if any side effects persist, it is important to contact your doctor.

If you have uncontrolled or untreated high blood pressure or red cell aplasia (a form of anaemia) caused by darbepoetin alfa or epoetin alfa, please notify your doctor prior to receiving Darbitop 25 Injection 0.42 ml to prevent any complications. Additionally, inform your doctor about all other medications you are currently taking that may influence the effectiveness of Darbitop 25 Injection 0.42 ml. Seek immediate medical attention if you experience weakness, lightheadedness, fatigue, shortness of breath, or if your skin appears pale.